Advertisement

Clinical Rheumatology

, Volume 35, Issue 5, pp 1281–1286 | Cite as

Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study

  • Giacomo Emmi
  • Rosaria Talarico
  • Giuseppe Lopalco
  • Rolando Cimaz
  • Fabrizio Cantini
  • Ombretta Viapiana
  • Ignazio Olivieri
  • Matteo Goldoni
  • Antonio Vitale
  • Elena Silvestri
  • Domenico Prisco
  • Giovanni Lapadula
  • Mauro Galeazzi
  • Florenzo Iannone
  • Luca Cantarini
Original Article

Abstract

Growing data have provided encouraging results on the use of interleukin (IL)-1 inhibitors in Behçet’s disease (BD). This study was aimed at reporting the largest experience with anti-IL-1 agents in BD patients. We evaluated 30 BD patients receiving treatment with anti-IL-1 agents. The primary aims of the study were to evaluate the efficacy of anakinra (ANA) and canakinumab (CAN) in a cohort of BD. The secondary aims were to evaluate the overall safety profile of the treatments, explore the timing of response to therapy and any adjustment of dosage and frequency of drugs studied, and investigate predictive factors of response to therapy. The frequency of first line therapy was 90 % with ANA and 10 % with CAN. The overall number of subjects in complete remission after 12 months of therapy with anti-IL-1 drugs was 13: 6 maintained the initial therapy regimen, 1 maintained the same initial anti-IL-1 drug with further therapeutic adjustments, and the remaining 6 shifted from ANA to CAN. Among them, 3 used CAN for at least 12 months without therapeutic adjustments, 1 had therapeutic adjustments, and 3 had an overall history of a 12-month complete remission. Adverse events (AEs) were reported in 15 % patients who received ANA, represented in all cases by local cutaneous reactions, while no AE were observed in patients who received CAN; we did not observe any serious AEs (SAEs) during the follow-up period. Our data have confirmed that the use of anti-IL-1β drugs is efficacious and safe with an overall acceptable retention on treatment.

Keywords

Anakinra Anti-interleukin-1 Behçet’s disease Biologics Canakinumab Therapy 

References

  1. 1.
    International Study Group for Behcet disease (1990) Criteria for diagnosis of Behcet’s disease. Lancet 335:1078–1080Google Scholar
  2. 2.
    Pineton de Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D (2012) New insights into the pathogenesis of Behçet’s disease. Autoimmun Rev 11:687–698CrossRefPubMedGoogle Scholar
  3. 3.
    Consolandi C, Turroni S, Emmi G, Severgnini M, Fiori J, Peano C et al (2015) Behçet’s syndrome patients exhibit specific microbiome signature. Autoimmun Rev 14:269–276CrossRefPubMedGoogle Scholar
  4. 4.
    Gül A (2005) Behçet’s disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy 4:81–83CrossRefPubMedGoogle Scholar
  5. 5.
    Tasliyurt T, Yigit S, Rustemoglu A, Gul U, Ates O (2013) Common MEFV gene mutations in Turkish patients with Behcet’s disease. Gene 530:100–103CrossRefPubMedGoogle Scholar
  6. 6.
    Amoura Z, Dodé C, Hue S, Caillat-Zucman S, Bahram S, Delpech M et al (2005) Association of the R92Q TNFRSF1A mutation and extracranial deep vein thrombosis in patients with Behçet’s disease. Arthritis Rheum 52:608–611CrossRefPubMedGoogle Scholar
  7. 7.
    Zou J, Guan JL (2014) Interleukin-1-related genes polymorphisms in Turkish patients with Behçet disease: a meta-analysis. Mod Rheumatol 24:321–326CrossRefPubMedGoogle Scholar
  8. 8.
    Alexoudi I, Kapsimali V, Vaiopoulos A, Kanakis M, Vaiopoulos G (2011) Evaluation of current therapeutic strategies in Behçet’s disease. Clin Rheumatol 30:157–163CrossRefPubMedGoogle Scholar
  9. 9.
    Caso F, Costa L, Rigante D, Lucherini OM, Caso P, Bascherini V et al (2014) Biological treatments in Behçet’s disease: beyond anti-TNF therapy. Mediators Inflamm 2014:107421CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Botsios C, Sfriso P, Furlan A, Punzi L, Dinarello CA (2008) Resistant Behçet disease responsive to anakinra. Ann Intern Med 149:284–286CrossRefPubMedGoogle Scholar
  11. 11.
    Emmi G, Silvestri E, Cameli AM, Bacherini D, Vannozzi L, Squatrito D et al (2013) Anakinra for resistant Behçet uveitis: why not? Clin Exp Rheumatol 31(3 Suppl 77):152–153PubMedGoogle Scholar
  12. 12.
    Cantarini L, Vitale A, Scalini P, Dinarello CA, Rigante D, Franceschini R et al (2013) Anakinra treatment in drug-resistant Behçet’s disease: a case series. Clin Rheumatol [Epub ahead of print]Google Scholar
  13. 13.
    Caso F, Rigante D, Vitale A, Lucherini OM, Cantarini L (2014) Efficacy of anakinra in refractory Behçet’s disease sacroiliitis. Clin Exp Rheumatol 32:S171PubMedGoogle Scholar
  14. 14.
    Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S (2012) Canakinumab in a patient with juvenile Behcet’s syndrome with refractory eye disease. Ann Rheum Dis 71:1589–1591CrossRefPubMedGoogle Scholar
  15. 15.
    Cantarini L, Vitale A, Borri M, Galeazzi M, Franceschini R (2012) Successful use of canakinumab in a patient with resistant Behçet’s disease. Clin Exp Rheumatol 30:S115PubMedGoogle Scholar
  16. 16.
    Vitale A, Rigante D, Caso F, Brizi MG, Galeazzi M, Costa L et al (2014) Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behçet’s disease: a case series. Dermatology 228:211–214CrossRefPubMedGoogle Scholar
  17. 17.
    Emmi G, Silvestri E, Ciucciarelli L, Squatrito D, Emmi L (2014) Reply: anti-IL1 blocking agents in drug-resistant Behçet’s syndrome: our little case series. Clin Exp Rheumatol 32(4 Suppl 84):S172PubMedGoogle Scholar
  18. 18.
    Gül A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A et al (2012) Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: an open-label pilot study. Ann Rheum Dis 71:563–566CrossRefPubMedGoogle Scholar
  19. 19.
    Cantarini L, Lopalco G, Caso F, Costa L, Iannone F, Lapadula G et al (2015) Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet’s disease. Autoimmun Rev 14:1–9CrossRefPubMedGoogle Scholar
  20. 20.
    Cantini F, Niccoli L, Goletti D (2014) Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol Suppl 91:47–55CrossRefPubMedGoogle Scholar
  21. 21.
    Botsios C (2005) Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. Autoimmun Rev 4:162–170CrossRefPubMedGoogle Scholar
  22. 22.
    Pagnini I, Bondi T, Simonini G, Giani T, Marino A, Cimaz R (2015) Successful treatment with canakinumab of a paediatric patient with resistant Behcet’s disease. Rheumatology. doi: 10.1093/rheumatology/kev197 PubMedGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2015

Authors and Affiliations

  • Giacomo Emmi
    • 1
  • Rosaria Talarico
    • 2
  • Giuseppe Lopalco
    • 3
  • Rolando Cimaz
    • 4
  • Fabrizio Cantini
    • 5
  • Ombretta Viapiana
    • 6
  • Ignazio Olivieri
    • 7
  • Matteo Goldoni
    • 8
  • Antonio Vitale
    • 9
  • Elena Silvestri
    • 1
  • Domenico Prisco
    • 1
  • Giovanni Lapadula
    • 3
  • Mauro Galeazzi
    • 9
  • Florenzo Iannone
    • 3
  • Luca Cantarini
    • 9
    • 10
  1. 1.Department of Experimental and Clinical MedicineUniversity of FlorenceFlorenceItaly
  2. 2.Department of Clinical and Experimental MedicineUniversity of PisaPisaItaly
  3. 3.Interdisciplinary Department of Medicine, Rheumatology UnitUniversity of BariBariItaly
  4. 4.Neurofarba DepartmentUniversity of Florence and AOU MeyerFlorenceItaly
  5. 5.Division of RheumatologyHospital of PratoPratoItaly
  6. 6.Unit of RheumatologyUniversity of VeronaVeronaItaly
  7. 7.Rheumatology Department of LucaniaSan Carlo Hospital of PotenzaPotenzaItaly
  8. 8.Department of Clinical and Experimental MedicineUniversity of ParmaParmaItaly
  9. 9.Research Center of Systemic Autoinflammatory Diseases and Behçet’s Disease Clinic, Department of Medical Sciences, Surgery and NeurosciencesUniversity of SienaSienaItaly
  10. 10.Rheumatology Unit, Department of Medical Sciences, Surgery and NeurosciencesUniversity of SienaSienaItaly

Personalised recommendations